Rebien: Here's why we expect a price fight in the US
Novo Nordisk expects to see significant pressure on prices in the US in the coming year due to increased competition, not least from a new product launch from one of its rivals.
BY STEFAN SINGH KAILAY
Growth on the crucial US market was anything but impressive in Novo Nordisk’s second quarter, and the Danish drug group will not be able to rely on higher price to lift it sales next year.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
